Pulling Back the Curtain on Clinical Trials & Diverse Patient Populations
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Andrew Alexis, co-chair of Skin of Color Update, and vice-chair for diversity and inclusion for the Weill Cornell Medical College Department of Dermatology. Dr. Alexis shares his take on how to address issues of mistrust that may impede clinical trial recruitment in diverse patient populations. Watch as he details why i …
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Andrew Alexis, co-chair of Skin of Color Update, and vice-chair for diversity and inclusion for the Weill Cornell Medical College Department of Dermatology. Dr. Alexis shares his take on how to address issues of mistrust that may impede clinical trial recruitment in diverse patient populations. Watch as he details why i … Continue reading "Pulling Back the Curtain on Clinical Trials & Diverse Patient Populations "
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Andrew Alexis, co-chair of Skin of Color Update, and vice-chair for diversity and inclusion for the Weill Cornell Medical College Department of Dermatology. Dr. Alexis points out that acne is the most common dermatologic condition for which patients with skin of color seek a dermatologist’s care. Hear why it’s impor … 
Check out this month’s issue highlights straight from the JDD Editor’s desk:
Assessing Implicit Bias in Dermatology analyses the results of a survey conducted with 220 dermatologists to determine the necessity for enhanced training and resources in order to support the increasingly diverse population.
Modified Fitzpatrick Scale-Skin Color and Reactivity presents a new system that can hel … 
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Valerie Callender, professor of dermatology at Howard University School of Medicine. Dr. Callender explains why patients from diverse populations may be hesitant to participate in clinical trials. She shares ways researchers can overcome barriers to recruitment, and why representation among the research team matters. Ac … 
Azelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris. It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm … 